Kuros Biosciences announced its strategic expansion into the extremities markets with the appointment of Jantzen Cole as Vice President of Market Development, Extremities, as well as the formation of a dedicated Surgeon Advisory Board.
With over two decades in the orthopedic and medical device fields, Mr. Cole brings experience in product innovation, brand-building and strategic market development. His expertise includes his most recent success as Vice President of Marketing at Artelon, where he drove notable revenue growth and brand recognition in the ankle instability market leading up to a recent acquisition by Stryker.
Under Mr. Cole’s leadership, Kuros will leverage its existing hospital approvals and established infrastructure, building on the company’s success in the spine market. Three of the MagnetOs formulations are already indicated for use beyond spine procedures. Supported by robust scientific, preclinical and clinical evidence, as well as ideal handling characteristics and a strong safety profile, MagnetOs is well positioned to address the need for improved fusion outcomes in extremities markets.
“We are thrilled to welcome Jantzen to the Kuros team. His extensive F&A expertise and proven success in launching transformative medical technologies align seamlessly with our vision,” said Chris Fair, Chief Executive Officer of Kuros Biosciences. “With our robust clinical data and support of our newly founded Surgeon Advisory Board, Kuros is well-positioned to expand globally beyond spine. We anticipate finishing 2024 with strong financial performance, strengthening our position as a premier advanced bone healing company across multiple musculoskeletal markets.”
Kuros Biosciences announced its strategic expansion into the extremities markets with the appointment of Jantzen Cole as Vice President of Market Development, Extremities, as well as the formation of a dedicated Surgeon Advisory Board.
With over two decades in the orthopedic and medical device fields, Mr. Cole brings experience in product...
Kuros Biosciences announced its strategic expansion into the extremities markets with the appointment of Jantzen Cole as Vice President of Market Development, Extremities, as well as the formation of a dedicated Surgeon Advisory Board.
With over two decades in the orthopedic and medical device fields, Mr. Cole brings experience in product innovation, brand-building and strategic market development. His expertise includes his most recent success as Vice President of Marketing at Artelon, where he drove notable revenue growth and brand recognition in the ankle instability market leading up to a recent acquisition by Stryker.
Under Mr. Cole’s leadership, Kuros will leverage its existing hospital approvals and established infrastructure, building on the company’s success in the spine market. Three of the MagnetOs formulations are already indicated for use beyond spine procedures. Supported by robust scientific, preclinical and clinical evidence, as well as ideal handling characteristics and a strong safety profile, MagnetOs is well positioned to address the need for improved fusion outcomes in extremities markets.
“We are thrilled to welcome Jantzen to the Kuros team. His extensive F&A expertise and proven success in launching transformative medical technologies align seamlessly with our vision,” said Chris Fair, Chief Executive Officer of Kuros Biosciences. “With our robust clinical data and support of our newly founded Surgeon Advisory Board, Kuros is well-positioned to expand globally beyond spine. We anticipate finishing 2024 with strong financial performance, strengthening our position as a premier advanced bone healing company across multiple musculoskeletal markets.”
Copy to clipboard 
